Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

[1]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[2]  Gaetano Rocco,et al.  Gefitinib in Non Small Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[3]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[4]  P. Baas,et al.  Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[6]  Y. Yatabe,et al.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.

[7]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Sonobe,et al.  Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. , 2006, The Journal of molecular diagnostics : JMD.

[9]  T. Utsunomiya,et al.  EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers , 2008, British Journal of Cancer.

[10]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[12]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[13]  Xiao Chen,et al.  Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy , 2005, Cell Research.

[14]  S. Kudoh,et al.  Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) , 2008, British Journal of Cancer.

[15]  園部 誠.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2006 .

[16]  H. Sugimura,et al.  EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.

[17]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[18]  Y. Yamashita,et al.  K-ras gene mutations in non-small cell lung cancer in Japanese. , 2000, Oncology Report.

[19]  H. Sasaki,et al.  EGFR and erbB2 mutation status in Japanese lung cancer patients , 2006, International journal of cancer.

[20]  M. Sonobe,et al.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2005, British Journal of Cancer.

[21]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[22]  Hyae-Young Kim,et al.  The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  J. Garst,et al.  Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer , 2005, Current oncology reports.

[24]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[25]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Kurth,et al.  The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. , 2008, Lung cancer.

[27]  T. Mitsudomi,et al.  Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers , 2008, General thoracic and cardiovascular surgery.

[28]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[29]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Y. Ohe,et al.  EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[32]  M. Spitz,et al.  Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[35]  Hai-sheng Zhou,et al.  Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[36]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[37]  Keunchil Park,et al.  A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer , 2006, Current medical research and opinion.

[38]  Shih-Feng Tsai,et al.  High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.

[39]  S. Hirohashi,et al.  Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma , 2007, Cancer science.

[40]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[41]  M. Sonobe,et al.  Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl‐Akt, and phosphoryl‐MAPK, and on the prognosis of patients with non‐small cell lung cancer , 2007, Journal of surgical oncology.

[42]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[43]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[44]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[45]  C. Chiu,et al.  Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. , 2006, Lung cancer.